Table 1.
Baseline characteristics of the study population.
| Parameters | Placebo (n = 14) | Pioglitazone (n = 14) | P value |
|---|---|---|---|
| Sex, M/F, n/n | 11/3 | 12/2 | 1.00 |
| Age, yr | 55.5 ± 10.9 | 56.2 ± 10.4 | 0.74 |
| Body mass index, kg/m2 | 23.7 ± 4.9 | 24.5 ± 2.9 | 0.58 |
| Systolic BP, mm Hg | 124 ± 19 | 121 ± 16 | 0.72 |
| Diastolic BP, mm Hg | 78 ± 10 | 76 ± 10 | 0.55 |
| Smoking | 9 | 12 | 0.39 |
| Fasting glucose, mmol/L | 5.28 ± 0.57 | 5.32 ± 0.37 | 0.86 |
| HbA1c, % | 5.42 ± 0.59 | 5.18 ± 0.49 | 0.25 |
| Total cholesterol, mmol/L | 3.78 ± 0.76 | 3.61 ± 0.45 | 0.48 |
| Triglycerides, mmol/L | 1.75 ± 1.27 | 1.81 ± 1.23 | 0.89 |
| HDL cholesterol, mmol/L | 0.90 ± 0.17 | 0.88 ± 0.20 | 0.74 |
| LDL cholesterol, mmol/L | 2.35 ± 0.67 | 2.15 ± 0.49 | 0.34 |
| Gensini score | 12.6 ± 8.8 | 10.9 ± 5.1 | 0.54 |
| hsCRP, mg/L | 4.0 (0.8, 11.8) | 2.9 (1.3, 12.3) | 0.58 |
| Treatment after stenting | |||
| Aspirin | 14 | 14 | 1.00 |
| Clopidogrel | 14 | 14 | 1.00 |
| Blocker | 12 | 14 | 0.48 |
| ACE inhibitors/ARBs | 14 | 14 | 1.00 |
| Statins | 14 | 14 | 1.00 |
Data are reported as mean ± SD, median (interquartile range), or n. BP, blood pressure; hs-CRP, high sensitivity C-reactive protein; ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker.